Accelerate Diagnostics Inc Valeur / Action
Quel est le Valeur / Action de Accelerate Diagnostics Inc?
Le Valeur / Action de Accelerate Diagnostics Inc est -0.71
Quelle est la définition de Valeur / Action?
La valeur comptable par action est l'actif de la société moins le passif divisé par le nombre d'actions en circulation.
The book value of a company is the value of its assets according to its balance sheet account balance. For assets, the value is based on the original cost of the asset less any depreciation, amortization or impairment costs made against the asset. Traditionally, a company's book value is its total assets minus intangible assets and liabilities. However, in practice, depending on the source of the calculation, book value may variably include goodwill, intangible assets, or both. The value inherent in its workforce, part of the intellectual capital of a company, is always ignored. The book value of a company may be also referred as with the term net asset value.
The book value per share is the the balance sheet equity value divided by the number of shares outstanding at the date of the balance sheet. Book value per share can be used to generate a measure of comprehensive earnings, when the opening and closing values are reconciled. The sale of shares/units by a business increases the total book value. Book value per share will increase if the additional shares are issued at a price higher than the pre-existing book value per share. The purchase of its own shares by a business will decrease total book value. Book value per share will decrease if more is paid for them than was received when originally issued. Dividends paid out will decrease book value per share value.
Valeur / Action des entreprises dans Health Care secteur sur NASDAQ par rapport à Accelerate Diagnostics Inc
Que fait Accelerate Diagnostics Inc?
accelerate diagnostics, inc. (nasdaq:axdx), is an in vitro diagnostics company focused on developing and commercializing innovative systems for the rapid identification and antimicrobial susceptibility testing of infectious pathogens. the company's revolutionary id/ast platform utilizes a proprietary process with both genomic and phenotypic detection technologies that significantly decreases time to result while achieving high sensitivity and specificity. in addition to the id/ast development pipeline, the company also owns and licenses its proprietary optichem™ surface coatings technology, which has numerous applications for binding in bio-analytical systems, such as microarrays.
Entreprises avec valeur / action similaire à Accelerate Diagnostics Inc
- FirstMark Horizon Acquisition a Valeur / Action de -0.72
- Lefteris Acquisition a Valeur / Action de -0.72
- Bridgetown a Valeur / Action de -0.72
- UniVision Engineering a Valeur / Action de -0.71
- Yunhong International a Valeur / Action de -0.71
- Catalyst Biosciences Inc a Valeur / Action de -0.71
- Accelerate Diagnostics Inc a Valeur / Action de -0.71
- Acorn a Valeur / Action de -0.70
- Andretti Acquisition a Valeur / Action de -0.70
- Healthcare Capital a Valeur / Action de -0.70
- Edify Acquisition a Valeur / Action de -0.70
- SVF Investment a Valeur / Action de -0.70
- Cineplex a Valeur / Action de -0.70